82 related articles for article (PubMed ID: 1904327)
1. The role of aldose reductase inhibition in diabetic neutrophil phagocytosis and killing.
Tebbs SE; Gonzalez AM; Wilson RM
Clin Exp Immunol; 1991 Jun; 84(3):482-7. PubMed ID: 1904327
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil phagocytosis and killing in insulin-dependent diabetes.
Wilson RM; Reeves WG
Clin Exp Immunol; 1986 Feb; 63(2):478-84. PubMed ID: 3084140
[TBL] [Abstract][Full Text] [Related]
3. The influence of aldose reductase on the oxidative burst in diabetic neutrophils.
Tebbs SE; Lumbwe CM; Tesfaye S; Gonzalez AM; Wilson RM
Diabetes Res Clin Pract; 1992 Feb; 15(2):121-9. PubMed ID: 1314160
[TBL] [Abstract][Full Text] [Related]
4. Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus.
Osar Z; Samanci T; Demirel GY; Damci T; Ilkova H
Exp Diabesity Res; 2004; 5(2):155-62. PubMed ID: 15203886
[TBL] [Abstract][Full Text] [Related]
5. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes.
Mazade MA; Edwards MS
Mol Genet Metab; 2001 Jul; 73(3):259-67. PubMed ID: 11461193
[TBL] [Abstract][Full Text] [Related]
6. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Boland OM; Blackwell CC; Clarke BF; Ewing DJ
Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
[TBL] [Abstract][Full Text] [Related]
7. Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
Umeda F; Noda K; Hashimoto T; Yamashita T; Nawata H
Diabetes Res; 1989 Nov; 12(3):125-9. PubMed ID: 2561396
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of polymorphonuclear leukocyte functions in diabetes mellitus--a comparative study of conventional radiometric function tests and low-light imaging systems.
Marhoffer W; Stein M; Schleinkofer L; Federlin K
J Biolumin Chemilumin; 1994; 9(3):165-70. PubMed ID: 7942121
[TBL] [Abstract][Full Text] [Related]
9. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
Ranganathan S; Krempf M; Feraille E; Charbonnel B
Diabete Metab; 1993; 19(2):257-61. PubMed ID: 8339858
[TBL] [Abstract][Full Text] [Related]
10. Fast anterograde axonal transport in wasted and non-wasted diabetic rats; effects of aldose reductase inhibition.
Whiteley SJ; Townsend J; Tomlinson DR; Willars GB
Diabetes Res; 1986 Nov; 3(9):447-52. PubMed ID: 2435444
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil sorbitol production impairs oxidative killing in diabetes.
Wilson RM; Tomlinson DR; Reeves WG
Diabet Med; 1987; 4(1):37-40. PubMed ID: 2951217
[TBL] [Abstract][Full Text] [Related]
12. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose.
Liu W; Liu P; Tao S; Deng Y; Li X; Lan T; Zhang X; Guo F; Huang W; Chen F; Huang H; Zhou SF
Arch Biochem Biophys; 2008 Jul; 475(2):128-34. PubMed ID: 18471986
[TBL] [Abstract][Full Text] [Related]
13. Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Song HP; Han XY; He Y; Kang TB; Wu HW
Chin Med J (Engl); 1991 Oct; 104(10):818-24. PubMed ID: 1661222
[TBL] [Abstract][Full Text] [Related]
14. Aldose reductase inhibitor zopolrestat restores allergic hyporesponsiveness in alloxan-diabetic rats.
Carvalho VF; Barreto EO; Serra MF; Cordeiro RS; Martins MA; Fortes ZB; e Silva PM
Eur J Pharmacol; 2006 Nov; 549(1-3):173-8. PubMed ID: 16979157
[TBL] [Abstract][Full Text] [Related]
15. Sorbitol, myo-inositol, and rod outer segment phagocytosis in cultured hRPE cells exposed to glucose. In vitro model of myo-inositol depletion hypothesis of diabetic complications.
Del Monte MA; Rabbani R; Diaz TC; Lattimer SA; Nakamura J; Brennan MC; Greene DA
Diabetes; 1991 Oct; 40(10):1335-45. PubMed ID: 1936595
[TBL] [Abstract][Full Text] [Related]
16. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil.
Phillips SA; Mirrlees D; Thornalley PJ
Biochem Pharmacol; 1993 Sep; 46(5):805-11. PubMed ID: 8373434
[TBL] [Abstract][Full Text] [Related]
17. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
18. The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats.
Sochor M; Kunjara S; McLean P
Biochem Pharmacol; 1988 Sep; 37(17):3349-56. PubMed ID: 2969732
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes.
Naruse K; Nakamura J; Hamada Y; Nakayama M; Chaya S; Komori T; Kato K; Kasuya Y; Miwa K; Hotta N
Exp Eye Res; 2000 Sep; 71(3):309-15. PubMed ID: 10973739
[TBL] [Abstract][Full Text] [Related]
20. The effect of aldose reductase inhibitor, statil, on hyperpermeability of iridial vessels in experimental galactosemic rats.
Terubayashi H; Akagi Y
Jpn J Ophthalmol; 1989; 33(3):343-7. PubMed ID: 2507812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
